tradingkey.logo

Natera Inc

NTRA
View Detailed Chart

169.400USD

+0.890+0.53%
Market hours ETQuotes delayed by 15 min
23.03BMarket Cap
LossP/E TTM

Natera Inc

169.400

+0.890+0.53%
Intraday
1m
30m
1h
D
W
M
D

Today

+0.53%

5 Days

+0.82%

1 Month

+6.92%

6 Months

+14.29%

Year to Date

+7.01%

1 Year

+33.90%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-12

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a very weak market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
8 / 72
Overall Ranking
95 / 4724
Industry
Healthcare Providers & Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 22 analysts
Buy
Current Rating
197.887
Target Price
+17.43%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 106.88% year-on-year.
Undervalued
The company’s latest PE is -88.59, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 131.96M shares, decreasing 0.30% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 12.62M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Natera, Inc. is a diagnostics company, which is focused on the development and commercialization of molecular testing services, applying its technology in the fields of women’s health, oncology and organ health. Its cell-free deoxyribonucleic acid (cfDNA) technology combines its molecular assays, which reliably measure many informative regions across the genome from samples as small as a single cell. The Company's product offerings include Panorama Non-Invasive Prenatal Test (NIPT), Vistara, Horizon Carrier Screening, Spectrum Preimplantation Genetics, Anora Miscarriage Test, Empower, and Prospera. The Company also offers Constellation, a cloud-based software platform that enables laboratory customers to gain access through the cloud to the Company’s algorithms and bioinformatics in order to validate and launch tests based on the Company’s technology. Its NIPT screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother.
Ticker SymbolNTRA
CompanyNatera Inc
CEOMr. Steven Leonard (Steve) Chapman
Websitehttps://www.natera.com/
KeyAI